-
1 Comment
Royalty Pharma plc is currently in a long term downtrend where the price is trading 5.6% below its 200 day moving average.
From a valuation standpoint, the stock is 99.4% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 7.6.
Royalty Pharma plc's total revenue rose by 25.9% to $572M since the same quarter in the previous year.
Its net income has dropped by 88.0% to $171M since the same quarter in the previous year.
Finally, its free cash flow grew by 1146.5% to $566M since the same quarter in the previous year.
Based on the above factors, Royalty Pharma plc gets an overall score of 3/5.
| Exchange | NASDAQ |
|---|---|
| Sector | Healthcare |
| Industry | Biotechnology |
| CurrencyCode | USD |
| ISIN | GB00BMVP7Y09 |
| Beta | 0.48 |
|---|---|
| Market Cap | 19B |
| PE Ratio | 17.28 |
| Target Price | 39.7414 |
| Dividend Yield | 2.7% |
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 14 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neuroscience, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for RPRX using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
